EUVIMEDOpdag EUVIMED
Übersichtsarbeit

Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment

Mengyao Wu, Yilan Zhao, Chi Zhang, Kanyi Pu iD

ACS Nano · 2024-10-22 · 18 (42) · 28502-28530

DOI: 10.1021/acsnano.4c09800 ↗

At a glance

Übersichtsarbeit in ACS Nano, published online on 2024-10-08. Written by Mengyao Wu and 3 co-authors. Institution: Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Engineering Research Center for Biomaterials and Medical Protective Material…. Major MEDLINE topics: Proteolysis. Cited 66 times so far (Crossref); 262 references. Funded by: Ministry of Education - Singapore, National Research Foundation Singapore, National Natural Science Foundation of China.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

Proteolysis targeting chimeras (PROTACs) represent a transformative class of therapeutic agents that leverage the intrinsic protein degradation machinery to modulate the hemostasis of key disease-associated proteins selectively. Although several PROTACs have been approved for clinical application, suboptimal therapeutic efficacy and potential adverse side effects remain challenging. Benefiting from the enhanced targeted delivery, reduced systemic toxicity, and improved bioavailability, nanomedicines can be tailored with precision to integrate with PROTACs which hold significant potential to facilitate PROTAC nanomedicines (nano-PROTACs) for clinical translation with enhanced efficacy and reduced side effects. In this review, we provide an overview of the recent progress in the convergence of nanotechnology with PROTAC design, leveraging the inherent properties of nanomaterials, such as lipids, polymers, inorganic nanoparticles, nanohydrogels, proteins, and nucleic acids, for precise PROTAC delivery. Additionally, we discuss the various categories of PROTAC targets and provide insights into their clinical translational potential, alongside the challenges that need to be addressed.

Subjects

MeSH terms (MEDLINE)

ProteolysisHumansNanotechnologyNanomedicineAnimalsProteostasisDrug Delivery SystemsNanoparticlesProteinsProteolysis Targeting Chimera

Author keywords

PROTACcancer therapydisease treatmentnanomedicinenanoplatformprotein homeostasisprotein of interesttargeted protein degradation

Substances

ProteinsProteolysis Targeting Chimera

Authors and institutions

  • Hubei Key Laboratory of Bioinorganic Chemistry and Materia Medica, Hubei Engineering Research Center for Biomaterials and Medical Protective Materials, School of Chemistry and Chemical Engineering, Huazhong University o…
  • School of Chemistry, Chemical Engineering and Biotechnology, Nanyang Technological University, 70 Nanyang Drive, 637457, Singapore.
  • Lee Kong Chian School of Medicine, Nanyang Technological University, 59 Nanyang Drive, 636921, Singapore.

ORCID profiles: Kanyi Pu

Funding

  • Ministry of Education - Singapore
  • National Research Foundation Singapore
  • National Natural Science Foundation of China

Cite

APA

Wu, M., Zhao, Y., Zhang, C., & Pu, K. (2024). Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment. ACS Nano, 18(42), 28502-28530. https://doi.org/10.1021/acsnano.4c09800

Vancouver

Wu M, Zhao Y, Zhang C, Pu K. Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment. ACS Nano. 2024;18(42):28502-28530. doi:10.1021/acsnano.4c09800

BibTeX
@article{Wu2024,
  author = {Wu, Mengyao and Zhao, Yilan and Zhang, Chi and Pu, Kanyi},
  title = {Advancing Proteolysis Targeting Chimera (PROTAC) Nanotechnology in Protein Homeostasis Reprograming for Disease Treatment},
  journal = {ACS Nano},
  year = {2024},
  volume = {18},
  number = {42},
  pages = {28502--28530},
  doi = {10.1021/acsnano.4c09800}
}
Start for free →